The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Andrew J Saxon - One of the best experts on this subject based on the ideXlab platform.
-
buprenorphine naloxone and methadone maintenance treatment outcomes for opioid analgesic heroin and combined users findings from starting treatment with agonist replacement therapies start
Journal of Studies on Alcohol and Drugs, 2013Co-Authors: Jennifer Sharpe Potter, Elise N Marino, Maureen Hillhouse, Suzanne Nielsen, Katharina Wiest, Catherine P Canamar, Judith Martin, Alfonso Ang, Rachael Baker, Andrew J SaxonAbstract:Objective:The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (Injector or non-Injector) of opioid use.Method:A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition.Results:Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated Injectors from non-Injectors. Further, Injectors were more likely to be using at end of treatment compared with non-Injectors. OA users were more likely to complete treatment compare...
-
buprenorphine naloxone and methadone maintenance treatment outcomes for opioid analgesic heroin and combined users findings from starting treatment with agonist replacement therapies start
Journal of Studies on Alcohol and Drugs, 2013Co-Authors: Jennifer Potter, Elise N Marino, Maureen Hillhouse, Suzanne Nielsen, Katharina Wiest, Catherine P Canamar, Judith Martin, Alfonso Ang, Rachael Baker, Andrew J SaxonAbstract:Objective The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (Injector or non-Injector) of opioid use. Method A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition. Results Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated Injectors from non-Injectors. Further, Injectors were more likely to be using at end of treatment compared with non-Injectors. OA users were more likely to complete treatment compared with heroin users and combined users. Non-Injectors were more likely than Injectors to complete treatment. There were no interactions between type of opioid used or injection status and treatment assignment (methadone or BUP) on either opioid use or treatment attrition. Conclusions Findings indicate that substance use severity differentiates heroin users from OA users and Injectors from non-Injectors. Irrespective of medication, heroin use and injecting are associated with treatment attrition and opioid misuse during treatment. These results have particular clinical interest, as there is no evidence of superiority of BUP over methadone for treating OA users versus heroin users.
Judith Martin - One of the best experts on this subject based on the ideXlab platform.
-
buprenorphine naloxone and methadone maintenance treatment outcomes for opioid analgesic heroin and combined users findings from starting treatment with agonist replacement therapies start
Journal of Studies on Alcohol and Drugs, 2013Co-Authors: Jennifer Sharpe Potter, Elise N Marino, Maureen Hillhouse, Suzanne Nielsen, Katharina Wiest, Catherine P Canamar, Judith Martin, Alfonso Ang, Rachael Baker, Andrew J SaxonAbstract:Objective:The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (Injector or non-Injector) of opioid use.Method:A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition.Results:Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated Injectors from non-Injectors. Further, Injectors were more likely to be using at end of treatment compared with non-Injectors. OA users were more likely to complete treatment compare...
-
buprenorphine naloxone and methadone maintenance treatment outcomes for opioid analgesic heroin and combined users findings from starting treatment with agonist replacement therapies start
Journal of Studies on Alcohol and Drugs, 2013Co-Authors: Jennifer Potter, Elise N Marino, Maureen Hillhouse, Suzanne Nielsen, Katharina Wiest, Catherine P Canamar, Judith Martin, Alfonso Ang, Rachael Baker, Andrew J SaxonAbstract:Objective The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (Injector or non-Injector) of opioid use. Method A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition. Results Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated Injectors from non-Injectors. Further, Injectors were more likely to be using at end of treatment compared with non-Injectors. OA users were more likely to complete treatment compared with heroin users and combined users. Non-Injectors were more likely than Injectors to complete treatment. There were no interactions between type of opioid used or injection status and treatment assignment (methadone or BUP) on either opioid use or treatment attrition. Conclusions Findings indicate that substance use severity differentiates heroin users from OA users and Injectors from non-Injectors. Irrespective of medication, heroin use and injecting are associated with treatment attrition and opioid misuse during treatment. These results have particular clinical interest, as there is no evidence of superiority of BUP over methadone for treating OA users versus heroin users.
Rachael Baker - One of the best experts on this subject based on the ideXlab platform.
-
buprenorphine naloxone and methadone maintenance treatment outcomes for opioid analgesic heroin and combined users findings from starting treatment with agonist replacement therapies start
Journal of Studies on Alcohol and Drugs, 2013Co-Authors: Jennifer Sharpe Potter, Elise N Marino, Maureen Hillhouse, Suzanne Nielsen, Katharina Wiest, Catherine P Canamar, Judith Martin, Alfonso Ang, Rachael Baker, Andrew J SaxonAbstract:Objective:The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (Injector or non-Injector) of opioid use.Method:A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition.Results:Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated Injectors from non-Injectors. Further, Injectors were more likely to be using at end of treatment compared with non-Injectors. OA users were more likely to complete treatment compare...
-
buprenorphine naloxone and methadone maintenance treatment outcomes for opioid analgesic heroin and combined users findings from starting treatment with agonist replacement therapies start
Journal of Studies on Alcohol and Drugs, 2013Co-Authors: Jennifer Potter, Elise N Marino, Maureen Hillhouse, Suzanne Nielsen, Katharina Wiest, Catherine P Canamar, Judith Martin, Alfonso Ang, Rachael Baker, Andrew J SaxonAbstract:Objective The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (Injector or non-Injector) of opioid use. Method A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition. Results Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated Injectors from non-Injectors. Further, Injectors were more likely to be using at end of treatment compared with non-Injectors. OA users were more likely to complete treatment compared with heroin users and combined users. Non-Injectors were more likely than Injectors to complete treatment. There were no interactions between type of opioid used or injection status and treatment assignment (methadone or BUP) on either opioid use or treatment attrition. Conclusions Findings indicate that substance use severity differentiates heroin users from OA users and Injectors from non-Injectors. Irrespective of medication, heroin use and injecting are associated with treatment attrition and opioid misuse during treatment. These results have particular clinical interest, as there is no evidence of superiority of BUP over methadone for treating OA users versus heroin users.
Alfonso Ang - One of the best experts on this subject based on the ideXlab platform.
-
buprenorphine naloxone and methadone maintenance treatment outcomes for opioid analgesic heroin and combined users findings from starting treatment with agonist replacement therapies start
Journal of Studies on Alcohol and Drugs, 2013Co-Authors: Jennifer Sharpe Potter, Elise N Marino, Maureen Hillhouse, Suzanne Nielsen, Katharina Wiest, Catherine P Canamar, Judith Martin, Alfonso Ang, Rachael Baker, Andrew J SaxonAbstract:Objective:The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (Injector or non-Injector) of opioid use.Method:A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition.Results:Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated Injectors from non-Injectors. Further, Injectors were more likely to be using at end of treatment compared with non-Injectors. OA users were more likely to complete treatment compare...
-
buprenorphine naloxone and methadone maintenance treatment outcomes for opioid analgesic heroin and combined users findings from starting treatment with agonist replacement therapies start
Journal of Studies on Alcohol and Drugs, 2013Co-Authors: Jennifer Potter, Elise N Marino, Maureen Hillhouse, Suzanne Nielsen, Katharina Wiest, Catherine P Canamar, Judith Martin, Alfonso Ang, Rachael Baker, Andrew J SaxonAbstract:Objective The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (Injector or non-Injector) of opioid use. Method A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition. Results Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated Injectors from non-Injectors. Further, Injectors were more likely to be using at end of treatment compared with non-Injectors. OA users were more likely to complete treatment compared with heroin users and combined users. Non-Injectors were more likely than Injectors to complete treatment. There were no interactions between type of opioid used or injection status and treatment assignment (methadone or BUP) on either opioid use or treatment attrition. Conclusions Findings indicate that substance use severity differentiates heroin users from OA users and Injectors from non-Injectors. Irrespective of medication, heroin use and injecting are associated with treatment attrition and opioid misuse during treatment. These results have particular clinical interest, as there is no evidence of superiority of BUP over methadone for treating OA users versus heroin users.
Catherine P Canamar - One of the best experts on this subject based on the ideXlab platform.
-
buprenorphine naloxone and methadone maintenance treatment outcomes for opioid analgesic heroin and combined users findings from starting treatment with agonist replacement therapies start
Journal of Studies on Alcohol and Drugs, 2013Co-Authors: Jennifer Sharpe Potter, Elise N Marino, Maureen Hillhouse, Suzanne Nielsen, Katharina Wiest, Catherine P Canamar, Judith Martin, Alfonso Ang, Rachael Baker, Andrew J SaxonAbstract:Objective:The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (Injector or non-Injector) of opioid use.Method:A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition.Results:Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated Injectors from non-Injectors. Further, Injectors were more likely to be using at end of treatment compared with non-Injectors. OA users were more likely to complete treatment compare...
-
buprenorphine naloxone and methadone maintenance treatment outcomes for opioid analgesic heroin and combined users findings from starting treatment with agonist replacement therapies start
Journal of Studies on Alcohol and Drugs, 2013Co-Authors: Jennifer Potter, Elise N Marino, Maureen Hillhouse, Suzanne Nielsen, Katharina Wiest, Catherine P Canamar, Judith Martin, Alfonso Ang, Rachael Baker, Andrew J SaxonAbstract:Objective The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (Injector or non-Injector) of opioid use. Method A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition. Results Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated Injectors from non-Injectors. Further, Injectors were more likely to be using at end of treatment compared with non-Injectors. OA users were more likely to complete treatment compared with heroin users and combined users. Non-Injectors were more likely than Injectors to complete treatment. There were no interactions between type of opioid used or injection status and treatment assignment (methadone or BUP) on either opioid use or treatment attrition. Conclusions Findings indicate that substance use severity differentiates heroin users from OA users and Injectors from non-Injectors. Irrespective of medication, heroin use and injecting are associated with treatment attrition and opioid misuse during treatment. These results have particular clinical interest, as there is no evidence of superiority of BUP over methadone for treating OA users versus heroin users.
